TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+2.99%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$671M
AUM Growth
+$671M
(-2.5%)
Cap. Flow
+$89.1M
Cap. Flow
% of AUM
13.28%
Top 10 Holdings %
Top 10 Hldgs %
38.66%
Holding
127
New
38
Increased
28
Reduced
16
Closed
24
Top Buys
| 1 |
Novo Nordisk
NVO
|
$21.5M |
| 2 |
Evolus
EOLS
|
$20.2M |
| 3 |
BLUE
bluebird bio
BLUE
|
$16.7M |
| 4 |
FLG
Flagstar Financial, Inc.
FLG
|
$14.5M |
| 5 |
Adicet Bio
ACET
|
$11.1M |
Top Sells
Sector Composition
| 1 | Healthcare | 91.26% |
| 2 | Financials | 6.75% |
| 3 | Real Estate | 0.31% |
| 4 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AnaptysBio
ANAB
$569M
| $44.2M | 6.59% | 2,032,561 -596,117 | -23% | -$13M |
|
|
BLUE
2
DELISTED
bluebird bio
BLUE
| $31.4M | 4.68% | 9,882,827 +5,247,299 | +113% | +$16.7M |
|
3
Mirum Pharmaceuticals
MIRM
$3.71B
| $28.1M | 4.19% | 1,170,000 +50,000 | +4% | +$1.2M |
|
|
4
Evolus
EOLS
$494M
| $27M | 4.03% | 3,197,399 +2,387,911 | +295% | +$20.2M |
|
5
Tarsus Pharmaceuticals
TARS
$2.47B
| $25.6M | 3.81% | 2,034,158 +32,573 | +2% | +$409K |
|
|
6
Novo Nordisk
NVO
$251B
| $21.5M | 3.2% | +135,000 | New | +$21.5M |
|
7
Moderna
MRNA
$9.37B
| $21M | 3.13% | 136,700 +56,700 | +71% | +$8.71M |
|
8
KalVista Pharmaceuticals
KALV
$678M
| $20.8M | 3.11% | 2,651,393 -545,053 | -17% | -$4.28M |
|
9
Immunocore
IMCR
$1.62B
| $20.1M | 2.99% | 405,600 | – | – |
|
10
Axsome Therapeutics
AXSM
$6.05B
| $19.7M | 2.94% | 320,000 | – | – |
|
|
ONC
11
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $18.3M | 2.73% | 85,000 | – | – |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $17.6M | 2.63% | 692,925 | – | – |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $16.2M | 2.42% | 300,000 +60,000 | +25% | +$3.25M |
|
|
FLG
14
Flagstar Financial, Inc.
FLG
$5.33B
| $14.5M | 2.16% | +1,606,600 | New | +$14.5M |
|
|
15
Adicet Bio
ACET
$59.9M
| $14.5M | 2.16% | 2,520,000 +1,920,000 | +320% | +$11.1M |
|
16
BioCryst Pharmaceuticals
BCRX
$1.74B
| $13.3M | 1.99% | 1,600,000 +150,000 | +10% | +$1.25M |
|
17
AstraZeneca
AZN
$248B
| $11.8M | 1.76% | 170,000 | – | – |
|
18
Altimmune
ALT
$338M
| $11.6M | 1.73% | 2,750,000 +49,550 | +2% | +$209K |
|
19
Vaxcyte
PCVX
$4B
| $11.2M | 1.68% | 300,000 | – | – |
|
20
Harmony Biosciences
HRMY
$2.12B
| $10.5M | 1.56% | 321,200 +40,000 | +14% | +$1.31M |
|
21
Eli Lilly
LLY
$657B
| $10.3M | 1.54% | 30,000 +10,000 | +50% | +$3.43M |
|
22
Pyxis Oncology
PYXS
$79.4M
| $9.95M | 1.48% | 2,481,662 -989,038 | -28% | -$3.97M |
|
23
Zymeworks
ZYME
$1.12B
| $9.94M | 1.48% | 1,100,000 +700,000 | +175% | +$6.33M |
|
|
JNCE
24
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $9.81M | 1.46% | +5,300,087 | New | +$9.81M |
|
25
BioAtla
BCAB
$26.7M
| $9.71M | 1.45% | 3,624,076 +500,000 | +16% | +$1.34M |
|